3 Results for "

IMMU-132

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "IMMU-132" in MCE Product Catalog:

11
11 Cited Publications
Cat. No.: HY-132254
CAS No.: 1491917-83-9
Purity:  99.13%
Synonyms: IMMU-132
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-132254A
CAS No.: 1491917-83-9
Purity:  96.61%
Synonyms: IMMU-132 (solution)
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
Cat. No.: HY-12758
CAS No.: 1346753-00-1
Purity:  99.16%
Target:  

BCRP

Research Areas:  

Cancer

YHO-13351 is an orally active ABCG2 inhibitor . YHO-13351 modulates the function of ABCG2, blocks BCRP-mediated compound efflux, downregulates the expression of breast cancer resistance protein at the post-transcriptional level, and reverses ABCG2-associated tolerance. YHO-13351 restores the toxicity of SN-38 to SN-38-resistant cancer cells and sensitizes cancer cells to Irinotecan. YHO-13351 is a water-soluble prodrug that is rapidly converted to YHO-13177 (HY-12757) in mice. YHO-13351 prolongs the median survival time of mice bearing cancer cell xenografts when combined with IMMU-132. YHO-13351 extends the survival time of tumor-bearing mice and inhibits the growth of xenograft tumors when combined with Irinotecan. YHO-13351 can be used for the research of breast cancer, gastric cancer, BCRP-mediated drug-resistant cancers, and cervical cancer .
loading...
    loading...